Figure 5From: ARA 290 Improves Symptoms in Patients with Sarcoidosis-Associated Small Nerve Fiber Loss and Increases Corneal Nerve Fiber DensityARA 290 treatment improves the BPI pain interference score. (A) Weekly pain interference scores significantly decline over the 4 wks of daily dosing for the ARA 290 compared with the placebo group. (B) A proportional responder display illustrates that the ARA 290 group responded to a larger extent at all levels of improvement.Back to article page